Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced a deeper collaboration with Verix, a company in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology’s commercial team intends to further leverage Verix’s innovative Tovana platform to support the anticipated fourth quarter 2025 U.S. commercialization of Lymphir, a novel immunotherapy approved by the U.S FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTOR:
- Citius Oncology Stockholders Approve Share Increase
- Citius Oncology Prepares LYMPHIR Launch for Q4 2025
- Citius Oncology announces distribution agreement with McKesson
- Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir
- Citius Oncology signs exclusive commercialization agreement with EVERSANA